CJ CheilJedang (097950)

CJ CheilJedang is Korea's No. 1 comprehensive food manufacturer, operating in three main business areas: Food, Bio, and Logistics. In the Food business, it produces and sells a wide range of products, from basic ingredients like sugar, flour, and cooking oil to seasonings, fermented pastes, processed meat products, fresh foods, rice-based processed foods, frozen foods, HMR (Home Meal Replacement), and health foods. 'Bibigo' and 'Hetbahn' are representative brands. The Bio business is responsible for the production and sale of amino acids such as lysine and tryptophan, as well as nucleic acids, and is pursuing the expansion of its high-margin specialty product portfolio. The Logistics business provides domestic and international logistics, container, and parcel delivery services through CJ Logistics. As of 2025, the revenue breakdown is 42% from Food, 15% from Bio, and 43% from Logistics. Key customers include general consumers, global feed companies, and businesses requiring domestic and international logistics services. CJ CheilJedang maintains a strong No. 1 position in the domestic food market based on powerful brand equity like 'Bibigo', and is leading the global K-food market, notably holding the No. 1 position in the U.S. frozen dumpling market. It is strengthening its core competitiveness through vertical integration, encompassing food raw material sourcing, R&D, production, logistics, and sales. Furthermore, it is securing ultra-superior competitiveness by expanding its high-margin specialty product portfolio in the Bio business through global production infrastructure and innovative R&D technology, and by focusing on the development of sustainable food and packaging. CJ CheilJedang's revenue decreased by 10.9% from KRW 30,079.5 billion in 2022 to KRW 26,822.4 billion in 2023, then showed signs of recovery with a slight increase of 1.5% to KRW 27,239.7 billion in 2024 and 0.4% to KRW 27,342.6 billion in 2025. Operating income decreased by 17.7% from KRW 1,664.7 billion in 2022 to KRW 1,369.9 billion in 2023, then increased by 6.0% to KRW 1,452.1 billion in 2024, but profitability deteriorated with a 15.1% decrease to KRW 1,233.6 billion in 2025. The operating income margin has been trending downwards from 5.53% in 2022 to 4.51% in 2025. Notably, net income continuously decreased from KRW 802.7 billion in 2022, turning into a deficit of KRW -417.0 billion in 2025. Examining the company's financial health, the debt-to-equity ratio improved from 160.33% in 2022 to 146.45% in 2024, but increased again to 157.50% in 2025, remaining at a high level. The current ratio continuously declined from 100.10% in 2022 to 80.96% in 2025, indicating a need for caution regarding short-term liquidity. ROE (Return on Equity) decreased from 6.96% in 2022 to 2.83% in 2024, and recorded -3.61% in 2025, showing a deterioration in its ability to generate profit from shareholders' equity. Despite sluggish domestic consumption and a downturn in the bio industry, CJ CheilJedang aims to transform into a global food company by accelerating the growth of its overseas food business. Specifically, it is pursuing a 'K-food new territory expansion' strategy centered on Global Strategic Products (GSP) such as dumplings, processed rice, and kimchi. In the Bio business segment, it plans to focus on recovering profitability by expanding its high-margin product portfolio and strengthening competitiveness through its global production infrastructure. The company intends to pursue overall profitability improvement through management efficiency enhancements.